0.7677
Coherus Oncology Inc stock is traded at $0.7677, with a volume of 1.42M.
It is up +5.64% in the last 24 hours and up +1.53% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
See More
Previous Close:
$0.7267
Open:
$0.7315
24h Volume:
1.42M
Relative Volume:
0.87
Market Cap:
$93.31M
Revenue:
$257.24M
Net Income/Loss:
$-237.89M
P/E Ratio:
-0.2953
EPS:
-2.6
Net Cash Flow:
$-175.17M
1W Performance:
+1.28%
1M Performance:
+1.53%
6M Performance:
-47.78%
1Y Performance:
-52.90%
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CHRS
Coherus Oncology Inc
|
0.7677 | 93.31M | 257.24M | -237.89M | -175.17M | -2.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-16-24 | Downgrade | UBS | Buy → Neutral |
Nov-17-23 | Initiated | Robert W. Baird | Outperform |
Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
Jul-24-23 | Initiated | Citigroup | Buy |
May-01-23 | Initiated | Truist | Buy |
Mar-28-23 | Upgrade | UBS | Neutral → Buy |
Jun-14-22 | Initiated | UBS | Neutral |
Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-16-20 | Initiated | BofA Securities | Neutral |
Apr-17-20 | Initiated | SunTrust | Buy |
Aug-13-19 | Initiated | Mizuho | Buy |
Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
Aug-02-19 | Reiterated | Maxim Group | Buy |
Jun-11-19 | Initiated | Barclays | Overweight |
May-07-19 | Initiated | H.C. Wainwright | Buy |
Aug-28-18 | Initiated | H.C. Wainwright | Buy |
Mar-09-18 | Reiterated | Maxim Group | Buy |
Aug-08-17 | Reiterated | JP Morgan | Overweight |
Jun-13-17 | Reiterated | Maxim Group | Buy |
May-05-17 | Initiated | BMO Capital Markets | Outperform |
Oct-19-16 | Initiated | Robert W. Baird | Outperform |
Sep-07-16 | Initiated | Maxim Group | Buy |
Jul-27-16 | Initiated | Citigroup | Buy |
Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovative Therapies | CHRS Stock News - GuruFocus
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):